Mitral Loop Cerclage
Venous blood from the lungs passes through the left atrium and is carried from the left ventricle to the aorta and throughout the body. When the left ventricle contracts, arterial blood is supplied to the aorta, and the mitral valve must be closed to prevent regurgitation to the ventricle. Mitral regurgitation (MR) is a phenomenon in which arterial blood flows back because the mitral valve is not completely closed due to external factors or aging.
When mitral regurgitation (MR) occurs, breathing problems, arrhythmia, and heart failure occur, and in severe cases, death. The number of patients with mitral regurgitation has increased rapidly since the age of 55, and the number of patients with mitral regurgitation is the largest, four times the number of patients with aortic valves.
Currently, Mitraclip is the leader in mitral regurgitation (MR) treatment through catheter-based technology, and the overall market size is estimated to reach $2.1 billion (2.5 trillion won) in 2024 with an average annual growth rate of 10% (As of 2018).